Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 9:5:832-838.
doi: 10.1016/j.toxrep.2018.08.003. eCollection 2018.

A comparison of the anti-diabetic potential of d-ribose-l-cysteine with insulin, and oral hypoglycaemic agents on pregnant rats

Abraham A A Osinubi  1 , Leke Jacob Medubi  1 , Edidiong N Akang  1 , Lawal K Sodiq  1 , Titilola A Samuel  2 , Taiwo Kusemiju  1 , James Osolu  3 , Danladi Madu  4 , Olufemi Fasanmade  4
Affiliations

A comparison of the anti-diabetic potential of d-ribose-l-cysteine with insulin, and oral hypoglycaemic agents on pregnant rats

Abraham A A Osinubi et al. Toxicol Rep. .

Abstract

Over 18% of pregnant women are affected by diabetes mellitus (DM) and Insulin has been the commonest drug used in its treatment. There are reports of noncompliance to insulin due to trypanophobia, with suggestions for the use of oral hypoglycaemic agents (OHAs). However, the opposing views about the benefits and risk of oral hypoglycaemic agents (OHAs) warrant a continuous search for an alternative regimen. Therefore, this study is aimed at comparing the antidiabetic effects of d-ribose-l-cysteine (riboceine) with vildagliptin, glibenclamide, metformin, glipizide and insulin in diabetes in pregnancy. Forty (40) female Sprague-Dawley (SD) rats were mated with twenty (20) male SD rats. Diabetes was induced by streptozotocin and the female SD rats were divided into 8 groups of five (5) rats each. The animals were administered either of the OHAs vildagliptin, glibenclamide, metformin, glipizide and riboceine for a period of 19 gestational days. The results showed that streptozotocin (STZ) significantly (p < 0.05) decreased the weights of the animals, increased malondialdehyde, blood glucose levels and altered reproductive hormones. These effects of STZ were better ameliorated in animals that received insulin and riboceine compared to the other OHAs. While progesterone levels were significantly (p < 0.05) higher in animals that received riboceine compared to insulin. Glibenclamide increased (p < 0.05) foetal weights compared to non-diabetic animals. In conclusion, glibenclamide may be a threat to mother`s life in the management of diabetes in pregnancy however, riboceine as well as vildagliptin, metformin and glipizide are effective oral hypoglycaemic agents which could serve as a potent adjuvant comparable to insulin in the management of diabetes during gestation.

Keywords: Diabetes; Glibenclamide; Glipizide; Metformin; Oxidative stress; Vildagliptin; d-Ribose-l-Cysteine.

PubMed Disclaimer

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Showing Initial and final body weights. ***p < 0.0001 within the group.
Fig. 2
Fig. 2
Showing progressive changes in blood glucose levels.
Fig. 3
Fig. 3
Showing the difference in blood glucose levels between groups. *p < 0.05 between groups; ***p < 0.0001 between groups; ***ab p < 0.0001 comparing groups with non-diabetic negative control and diabetic positive control groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rydén L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., Deaton C., Escaned J., Hammes H.-P., Huikuri H. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2013;34:3035–3087. - PubMed
    1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:S81–S90. - PubMed
    1. Centers For Disease Control Prevention . US Department of Health and Human Services, Centers for Disease Control and Prevention; Atlanta, GA: 2011. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011; p. 201.
    1. Hoch E., Rusu V., Schreiber S.L., Florez J.C., Jacobs S.B., Lander E.S. Type 2 diabetes-associated variants disrupt function of SLC16A11, a proton-coupled monocarboxylate transporter, through two distinct mechanisms. Faseb J. 2017;31 950.2-950.2.
    1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010;87:4–14. - PubMed

LinkOut - more resources